Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)
Mandate

Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)

November 03, 2014

Vinge has advised HealthCap VI L.P in connection with the execution of an investment agreement with Cortendo AB (publ) (“Cortendo”). The investment will be effected through a directed new issue of shares to HealthCap and other investors.

The new issue must be approved by a shareholders’ meeting of Cortendo and the meeting is expected to be held on or about 1 December 2014.Cortendo is a Swedish biopharmaceutical company which has its base in the United States.

Vinge’s team consisted of responsible partner Johan Winnerblad and associate Alex Miler.

Related

Vinge advises Aspo on its acquisition of Swed Handling

 Vinge advises Aspo, listed on Nasdaq Helsinki, in the transaction whereby Aspo's subsidiary Telko expands its chemicals business in Sweden by acquiring Swed Handling, a leading Swedish chemical distributor, from TeRa Invest. As part of the transaction, Aspo’s subsidiary Leipurin expands its food industry business in Sweden, via the technical food ingredient distributor Kebelco, which is a subsidiary of Swed Handling. The closing of the transaction is subject to customary regulatory approvals.
April 30, 2024

Vinge advises on the sale of Vinnergi Holding AB

 Vinge has advised Sobro and other shareholders in connection with the sale of Vinnergi Holding AB to Polaris, a Nordic investment firm. In connection with the transaction, the management and employees are reinvesting a significant portion to further develop the company. The Vinnergi Group conducts operations in technology consulting and software development in Sweden, with a particular focus on telecoms, energy and real estate.
April 30, 2024

Vinge has advised Pareto Securities in connection with a rights issue in Episurf Medical

 Vinge has advised Pareto Securities in connection with a partially secured rights issue of units of up to approximately SEK 120 million in Episurf Medical.
April 24, 2024